Follow us on Twitter
twitter icon@FreshPatents


Mammal patents

      

This page is updated frequently with new Mammal-related patent applications.




 High-resolution three-dimensional imaging of mammalian hearts patent thumbnailHigh-resolution three-dimensional imaging of mammalian hearts
Methods and materials for high-resolution three-dimensional imaging of mammalian tissues, such as heart and intestine, are described. Both methods of tissue preparation for imaging and methods of imaging are described, as well as kits comprising materials and media for use in the methods..
University Of Washington


 Compositions, methods and kits for characterizing and screening for small cell ovarian carcinoma patent thumbnailCompositions, methods and kits for characterizing and screening for small cell ovarian carcinoma
The present invention relates compositions, methods and kits for characterizing the type of and screening for the existence or predisposition for small cell carcinoma of the ovary, hypercalcemic type (sccoht). The invention also relates to a method of treating a mammalian subject having sccoht or a predisposition for sccoht..
British Columbia Cancer Agency Branch


 Cell culture process for producing a protein patent thumbnailCell culture process for producing a protein
The invention provides the mammalian cell culture process for the production of monoclonal antibodies and fusion proteins wherein the mammalian cell is cultured in suitable cell culture conditions specifically maintaining monophasic temperature.. .
Lupin Limited


 Multi-lineage hematopoietic precursor cell production by genetic programming patent thumbnailMulti-lineage hematopoietic precursor cell production by genetic programming
The present disclosure generally regards methods and compositions for providing multi-lineage hematopoietic precursor cells from pluripotent stem cells (pscs). The pscs comprise an expression construct encoding an ets/erg gene, gata2 and hoxa9.
Cellular Dynamics International, Inc.


 Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy patent thumbnailExpansion of lymphocytes with a cytokine composition for active cellular immunotherapy
The present invention relates to a composition for expanding lymphocytes comprising at least two types of cytokines selected from interleukin 2 (il-2), interleukin 15 (il-15) and interleukin 21 (il-21). It further relates to a method of preparing a population of clinically relevant lymphocytes, comprising the steps of: obtaining a body sample from a mammal in particular a tissue sample or body liquid sample, comprising at least one lymphocyte and optionally separating the cells in the body sample, culturing the body sample in-vitro to expand and/or stimulate lymphocytes in the sample wherein the culturing comprises using il-2, il-15 and/or il-21, and optionally determining the presence of clinically relevant lymphocyte in the cultured sample.
Polybiocept Ab


 Method of manufacturing or differentiating mammalian pluripotent stem cellsor progenitor cells using a hollow fiber bioreactor patent thumbnailMethod of manufacturing or differentiating mammalian pluripotent stem cellsor progenitor cells using a hollow fiber bioreactor
The present disclosure provides a method of manufacturing and differentiating mammalian stern cells, and in one embodiment human induced pluripotent stern cells (ipsc), e.g., manufacturing neuron progenitors, e.g., derived from ipsc, on a large scale by the use of an automated hollow fiber reactor system. In one embodiment, human ipsc that can be differentiated into cardiomyocytes or neuron progenitors are provided.
Stemonix Inc.


 Methods of modulating inflammasome activity to treat inflammatory conditions patent thumbnailMethods of modulating inflammasome activity to treat inflammatory conditions
Compositions and methods for reducing inflammation in the central nervous system (cns) of a mammal that has been subjected to a stroke, traumatic injury to the cns such as traumatic brain injury (tbi), spinal cord injury (sci), or having an autoimmune or cns disease have been developed. The compositions and methods described herein include antibodies that specifically bind to at least one component (e.g., asc, nalp1) in a mammalian inflammasome (e.g., the nalp1 inflammasome) and have use as treatments for sci, tbi, stroke, and autoimmune and cns diseases in a mammal.
University Of Miami


 Method and  performing a peripheral nerve block patent thumbnailMethod and performing a peripheral nerve block
A system for infusing medication into a mammalian subject is provided. The system includes an injection system for controlling a flow of fluid from a fluid reservoir to a needle.
Milestone Scientific, Inc.


 Drug infusion device with visual indicator of fluid pressure patent thumbnailDrug infusion device with visual indicator of fluid pressure
A system for infusing medication into a mammalian subject is provided. The system includes an injection system for controlling a flow of fluid from a fluid reservoir to a needle.
Milestone Scientific, Inc.


 Influenza vaccine, composition, and methods of use patent thumbnailInfluenza vaccine, composition, and methods of use
The invention relates to compositions and vaccines that include a mutated bordetella strain for treating or preventing an influenza infection in a mammal. In addition, the invention further provides methods for protecting a mammal against infection by influenza and/or eliciting an immune response against an influenza virus in a mammal using the composition or vaccine..
National University Of Singapore


Thermostabilization of proteins

Provided are compositions comprising a cocaine esterase (coce) and a compound that thermostabilizes the coce. Also provided are methods of thermostabilizing a cocaine esterase.
The Regents Of The University Of Michigan

Methods and materials for reducing supression of immune function

This document provides methods and materials involved in reducing suppression of immune function in mammals. For example, methods and materials for (a) identifying a mammal as having an elevated level of cd14+/dr− cells (e.g., cd14+/dr− monocytes) and (b) administering ru486 (mifepristone; or drugs with a similar functional profile) to the identified mammal under conditions that change the ratio of cd14+/hla-dr− cells to cd14+/hla-dr+ cells as well as methods and materials for (a) identifying a mammal as being likely to experience an elevated level of cd14+/dr− cells (e.g., cd14+/dr− monocytes) and (b) administering ru486 (mifepristone; or drugs with a similar functional profile) to the identified mammal under conditions that reduce the degree to which the mammal develops cd14+/dr− cells are provided..
Mayo Foundation For Medical Education And Research

Formulations and methods for treating high intraocular pressure

Disclosed herein are methods of treating a mammal in need of a reduction in intraocular pressure by administering an intraocular formulation including a therapeutically effective amount of norketotifen for the reduction of intraocular pressure to the eye of the mammal in need thereof, wherein the intraocular formulation includes about 0.02 wt % to about 1.0 wt % norketotifen or a salt or an isomer thereof, calculated as the norketotifen free base. In certain aspects, the intraocular formulation is free from any added preservative and the intraocular formulation is self-preserving.
Bridge Pharma, Inc.

Method for suppressing diabetes and/or hepatic lipids using tormentic acid

Provided is a method for suppressing diabetes and/or hepatic lipids in a mammal to lower blood glucose levels and hepatic total lipids and triacylglycerol contents by increasing amp-activated protein kinase (ampk) phosphorylation in both skeletal muscle and liver tissue, and akt phosphorylation and membraneprotein levels of glucose transporter 4 (glut4) in skeletal muscle. The method comprises administrating to the mammal an effective amount of tormentic acid or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier..

Nanoparticulate complex of nicotine and cerium oxide and use thereof

Disclosed are particles comprising a complex of nicotine and cerium oxide and a biodegradable coating comprising agglutinin. Also disclosed is a method of treating or preventing neurodegenerative or neurological disorders in a mammal in need thereof, comprising administering to the mammal a therapeutically effective amount of the particles..
The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. .
Kymab Limited

Mouse model of retinal degeneration

The invention is directed to a method of producing a non-human mammal having one or more pathological characteristics of retinal degeneration and/or age-related macular degeneration. In particular, the invention provides a method of producing a non-human mammal having age-related macular degeneration (amd).
The Cleveland Clinic Foundation

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. .
Kymab Limited

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. .
Kymab Limited

Non-standard insulin analogues

An insulin analogue comprises a b-chain polypeptide containing a cyclohexanylalanine substitution at position b24 and optionally containing additional amino-acid substitutions at positions a8, b28, and/or b29. A proinsulin analogue or single-chain insulin analogue containing a b domain containing a cyclohexanylalanine substitution at position b24 and optionally containing additional amino-acid substitutions at positions a8, b28, and/or b29.
Case Western Reserve University

Apparatus and treating cancer cells and bacteria in mammals including humans

Bacteria, cancer cells, fungus and other harmful cells located beneath the surface of a mammal body can be effectively destroyed by passing an electrical current through the area to be treated. Electrodes are positioned on either side of the area to be treated, for example, gums, fingers, arms, legs, feet and torso, and an electric current is caused to flow between the electrodes and through the area to be treated.
Bnr Technology Development, Llc

Collagen matrix for cell therapy

The invention relates to the use of an active collagen matrix for culturing mammalian cells and the use of the active collagen matrix and cells for the treatment of disease.. .
Warsaw Orthopedic, Inc.

Chemical induction of lactation in prepubescent non-human mammals

The present invention describes a method of inducing lactation in non-human mammals by using a single administrations of an estrogen compound, a dopaminergic antagonist, and oxytocin. For example, the estrogen compound may be a long acting composition and is administered at least one week before the dopaminergic antagonist.

Methods for the prevention or treatment of vessel occlusion injury

This invention provides methods of preventing or treating cardiac ischemia-reperfusion injury in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof, wherein the peptide is d-arg-2 6-dmt-lys-phe-nh2 (ss-31)..
Stealth Peptides International, Inc.

Methods for preventing or treating insulin resistance

The invention provides methods of preventing or treating insulin resistance in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1..
East Carolina University

Use of free radical scavengers for protecting and treating skin and hair damages caused by chemotherapy

The invention also concerns a method for the protection or treatment of skin and hair damages of a mammal caused by chemotherapy. The invention further relates to a kit for the protection or treatment of hair damages caused by chemotherapeutic treatment consisting of a topical composition comprising microparticles together with free radical scavengers and a shampoo for an effective hair cleaning and supporting the hair treatment.

Compositions, packaged pharmaceuticals, and methods of using hedgehog pathway modulators for the sensitization of resistant tumors

Compositions, packaged pharmaceuticals, and methods of treatment by the sensitization of resistant tumors are provided. The compositions comprise a combination of a hedgehog pathway modulator, such as itraconazole, and a chemotherapeutic agent.

Use of retinoic acid and analogs thereof to treat central neural apneas

Described is a method of inhibiting central apnea, central hypopnea or obstructive sleep apnea in a mammal. The method includes the step of administering to a mammal a central apnea inhibitory-effective, central hypopnea inhibitory-effective or obstructive sleep apnea inhibitory-effective amount of a composition comprising at least one retinoid or retinoid or retinoic acid receptor agonist..
Wisconsin Alumni Research Foundation

Methods of inhibiting, protecting against, or treating uvr-induced skin damage

One aspect of the invention provides a method of inhibiting, protecting against, or treating uvr-induced skin damage in a mammal at risk of developing uvr-induced skin damage. The method includes the step of topically administering a pharmaceutical or cosmetic composition including an effective amount of a syk kinase inhibitor to said mammal.
Drexel University

Skin treatment composition

A composition for application to mammalian skin. The composition can include an emulsion comprising an oil phase.
3m Innovative Properties Company

Measuring device and measuring physiological data of a mammal

A measuring device for measuring physiological data of a mammal comprising a measuring unit, to be worn by the mammal, with a first and second module. The first module comprises a light source and the second module comprises a sensor unit for measuring an intensity of a fraction of the light delivering a measuring signal.
N.v. Nederlandsche Apparatenfabriek Nedap

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. .
Kymab Limited

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. .
Kymab Limited

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. .
Kymab Limited

Methods and reagents for analyzing protein-protein interfaces

The present disclosure provides methods and reagents useful for analyzing protein-protein interfaces such as interfaces between a presenter protein (e.g., a member of the fkbp family, a member of the cyclophilin family, or pin1) and a target protein. In some embodiments, the target and/or presenter proteins are intracellular proteins.
Warp Drive Bio, Inc.

Methods and materials for detecting gene amplification

This document relates to methods and materials involved in detecting gene amplification in a mammal. For example, methods and materials for detecting amplification at cpm and mdm2 loci to determine the presence or absence of a malignant lipomatous neoplasm in a mammal are provided..
Mayo Foundation For Medical Education And Research

Aav vectors for vascular gene therapy in coronary heart disease and peripheral ischaemia

The invention relates to the provision of a gene therapy for coronary heart disease and peripheral ischemia in mammals. One embodiment is an adeno-associated viral vector (aav vector) comprising a first gene encoding a myocardin-related transcription factor a (mrtf-a).

Inhibiting gene expression with dsrna

The present invention relates to the specific inhibition of gene expression in mammals by bringing the target gene into contact with double stranded rna (dsrna).. .
Cancer Research Technology Limited

Methods and devices for simultaneous optical irradiation and oscillating magnetic field radiation of a target

The present disclosure is generally directed to methods and devices for the precise and simultaneous optical irradiation and oscillating magnetic field radiation of a target, such as mammalian cells and/or nanostructures.. .
Southeast Missouri State University

Animal models and therapeutic molecules

The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. .
Kymab Limited

Use of antibody conjugates

Provided herein are methods for inducing growth arrest or apoptosis in cancer cells in a subject. Further provided are methods of inhibiting or treating metastasis of a cancer cell in a subject.
The Regents Of The University Of California

Human placental collagen compositions, and methods of making and using the same

The present invention provides compositions comprising human placental telopeptide collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal..
Anthrogenesis Corporation

Fibroblast growth factor mutants having improved functional half-life and methods of their use

Mutant fibroblast growth factor (fgf) proteins having a polypeptide sequence with a high sequence identity to proteins encoded by members of the fgf-1 subfamily of genes from a mammalian species, such as human, and with a specific amino acid substitution of an alanine at a position corresponding to amino acid position 66 of human fgf-1 with a cysteine and/or a specific amino acid substitution of a phenylalanine at a position corresponding to amino acid position 132 of human fgf-1 with a tryptophan (based on the 140 amino acid numbering scheme of human fgf-1) are provided. Other amino acid mutations or substitutions may be combined.
Florida State University Research Foundation, Inc.

Fibroblast growth factor mutants having improved functional half-life and methods of their use

Mutant fibroblast growth factor (fgf) proteins having a polypeptide sequence with a high sequence identity to proteins encoded by members of the fgf-1 subfamily of genes from a mammalian species, such as human, and with a specific amino acid substitution of an alanine at a position corresponding to amino acid position 66 of human fgf-1 with a cysteine and/or a specific amino acid substitution of a phenylalanine at a position corresponding to amino acid position 132 of human fgf-1 with a tryptophan (based on the 140 amino acid numbering scheme of human fgf-1) are provided. Other amino acid mutations or substitutions may be combined.
Florida State University Research Foundation, Inc.

Compositions and methods of use of phorbol esters for treatment of stroke

Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects..

Apparatus and treating cancer cells and bacteria in mammals including humans

Bacteria, cancer cells, fungus and other harmful cells located beneath the surface of a mammal body can be effectively destroyed by passing an electrical current through the area to be treated. Electrodes are positioned on either side of the area to be treated, for example, gums, fingers, arms, legs, feet and torso, and an electric current is caused to flow between the electrodes and through the area to be treated.
Bnr Technology Development, Llc

Antimicrobial articles produced by additive manufacturing

An antibiotic-eluting article for implantation into a mammalian subject, produced by an additive manufacturing process wherein a polymeric material is concurrently deposited with a selected antibiotic. The additive manufacturing process may be a selective laser sintering process or a selective laser melting process or a selective heat sintering process or an electron beam melting process.
Orthopaedic Innovation Centre

Methods and compositions for managing reproduction

The present invention relates to methods, compositions and kits for controlling, managing or manipulating the non-human mammalian female reproductive cycle. The methods include oestrus induction and/or synchronisation, induction of ovulation and/or superovulation and optionally further includes a method of providing an immunopermissive uterine environment prior to insemination or implantation of embryos..
Ostara Biomedical Ltd

Fibroblast growth factor mutants having improved functional half-life and methods of their use

Mutant fibroblast growth factor (fgf) proteins having a polypeptide sequence with a high sequence identity to proteins encoded by members of the fgf-1 subfamily of genes from a mammalian species, such as human, and with a specific amino acid substitution of an alanine at a position corresponding to amino acid position 66 of human fgf-1 with a cysteine and/or a specific amino acid substitution of a phenylalanine at a position corresponding to amino acid position 132 of human fgf-1 with a tryptophan (based on the 140 amino acid numbering scheme of human fgf-1) are provided. Other amino acid mutations or substitutions may be combined.
Florida State University Research Foundation, Inc.

Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates

Biocompatible hydrogel capsules encapsulating mammalian cells having a diameter of greater than 1 mm, and optionally a cell free core, are disclosed which have reduced fibrotic overgrowth after implantation in a subject. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject..
The Children's Medical Center Corporation

Use of nanoparticles coated with red blood cell membranes to treat hemolytic diseases and disorders

The present invention relates to methods, combinations and pharmaceutical compositions for treating or preventing a hemolytic disease or condition in a mammal, wherein: said hemolytic disease or condition is caused by an attack of said mammal's red blood cells by said mammal's own body, or said mammal is a pregnant mammal and said hemolytic disease or condition of a fetus of said pregnant mammal is caused by an attack of said fetus' red blood cells by an antibody of said pregnant mammal, or said mammal is a baby and said hemolytic disease or condition of said baby is caused by an attack of said baby's red blood cells by an antibody of said baby's mother. The exemplary hemolytic diseases or conditions include hemophagocytic lymphohistiocytosis, an autoimmune disease or condition, or a hereditary hemolytic disease or disorder..
Cellics Therapeutics, Inc.

Method for treating noise-induced hearing loss (nihl)

A method for treating noise-induced hearing loss (nihl) includes the step administering a composition to the mammal, wherein the composition consists essentially of a biologically effective amount of vitamin a, vitamin e, vitamin c, a vasodilator comprising magnesium, and, optionally, a withanolide, and/or resveratrol.. .
Universidad De Castilla-la Mancha, Instituto De Investigación En Discapacidades Neurológicas-idine

Galactoside inhibitors for new uses

Provided is a method for treatment or prevention of α-synucleinopathies in a mammalian subject, the method comprising administering a therapeutically effective amount of at least one composition to the subject, wherein the composition comprises a molecule for pharmacological modulation of galectin activity in a mammalian brain.. .
Galecto Biotech Ab

Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds

A method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+ non-small cell lung cancer in a mammal by administering a solid dispersion comprising an amorphous thienotriazolodiazepine compound of the formula (1) wherein r′ is alkyl having a carbon number of 1-4, r2 is a hydrogen atom; a halogen atom; or alkyl having a carbon number of 1-4 optionally substituted by a halogen atom or a hydroxyl group, r3 is a halogen atom; phenyl optionally substituted by a halogen atom, alkyl having a carbon number of 1-4, alkoxy having a carbon number of 1-4 or cyano; —nr 5-{ch 2)m-, —r6 wherein r5 is a hydrogen atom or alkyl having a carbon number of 1-4, m is an integer of 0-4, and r6 is phenyl or pyridyl optionally substituted by a halogen atom.. .
Oncoethix Gmbh

Combination of phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

The present invention relates to a pharmaceutical combination comprising a phosphatidylinositol-3-kinase (pi3k) inhibitor compound which is a 2-carboxamide cycloamino urea derivative or a pharmaceutically acceptable salt thereof and at least one mammalian target of rapamycin (mtor) inhibitor or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising such a combination; and the uses of such a combination in the treatment proliferative diseases, more specifically of mammalian target of rapamycin (mtor) kinase dependent diseases.. .
Novartis Ag

Composition including indoprofen and use thereof

A method of increasing pgc-1α expression in a mammalian cell, the method comprising administering an effective amount of indoprofen, a pharmaceutically acceptable salt thereof, or a solvate thereof to the cell.. .
Research & Business Foundation Sungkyunkwan University

Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents

This invention is directed to pharmaceutical compositions for topical administration to a mammal, wherein the pharmaceutical compositions comprise a spiro-oxindole compound, as an enantiomer, a racemate or a non-racemic mixture, or a pharmaceutically acceptable salt thereof. These pharmaceutical compositions are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions..
Xenon Pharmaceuticals Inc.





Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Mammal for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Mammal with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.3724

file did exist - 2391

0 - 1 - 57